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To analyze the sociodemographic and organizational factors influencing participation in 
population-based colorectal cancer screening programs (CRCSP) in Spain, a retrospective study 
was conducted in a cohort of people invited to participate in the first 3 screening rounds of 6 
CRCSP from 2000-2012. Mixed logistic regression models were used to analyze the relationship 
between sociodemographic and organizational factors, such as the type of fecal occult blood 
test (FOBT) used and the FOBT delivery type. The analysis was performed separately in groups 
(Initial Screening-first invitation, Subsequent invitation for previous never-responders, 
Subsequent invitation-regular, Subsequent invitation-irregular intervals). The results showed 
that, in the Initial screening-first invitation group, participation was higher in women than in 
men in all age groups (OR 1.05 in persons aged 50-59 years and OR 1.12 in those aged 60-69 
years). Participation was also higher when no action was required to receive the FOBT kit, 
independently of the type of screening (Initial screening-first invitation [OR 2.24], Subsequent 
invitation for previous never-responders [OR 2.14], Subsequent invitation-regular [OR 2.03], 
Subsequent invitation-irregular intervals [OR 9.38]) and when quantitative rather than 
qualitative immunological FOBT (FIT) was offered (Initial screening-first invitation [OR 0.70], 
Subsequent invitation for previous never-responders [OR 0.12], Subsequent invitation-regular 
[OR 0.20]) or guaiac testing (Initial screening-first invitation [OR 0.81], Subsequent invitation 
for previous never-responders [OR 0.88], Subsequent invitation-regular [OR 0.73]). In 
conclusion, the results of this study show that screening participation could be enhanced by 



























Colorectal cancer (CRC) is one of the most common malignancies in developed countries and 
the incidence of CRC in Spain is higher than that of any other cancer when both men and 
women are considered together. CRC is the third most common cancer in men after prostate 
and lung cancer, and is the second most common in women after breast cancer (Ferlay et al., 
2015). 
Studies performed since the 1990s have shown that the fecal occult blood test (FOBT) and 
flexible sigmoidoscopy contribute to the early detection of CRC and therefore to reducing 
associated mortality (Heresbach et al., 2006; Mandel et al., 1993; Saito el al., 1995; Atkin et al., 
2010; Segnan et al,. 2002; Kronborg et al.,1996;Hardcastle et al.,1996). Currently, the World 
Health Organization and the European Union (Wilson et al., 1968) recommend CRC screening 
programs (CRCSP). The expected long-term benefit of these programs is a reduction in overall 
and CRC-specific mortality and a decrease in the incidence of this tumor (Pan et al., 2016). 
The European Commission has drawn up guidelines for quality assurance in CRC screening and 
diagnosis (Segnan et al., 2010). This document establishes the recommendations, criteria and 
standards that should be achieved by organized population-based screening programs. 
Because assessment of the impact of these programs requires a long time lapse since their 
initiation, monitoring of participation and detection rates is essential to allow prediction of 
their impact. If CRCSP maintain high participation rates and adhere to standards for detection, 
mortality can be expected to be reduced after 10 years of screening (McClements et al., 2012; 
Zorzi et al., 2014). 
CRCSP are recent in Europe and in Spain have been implemented in the last few years. 
Consequently little research has been conducted on the possible influence of 
sociodemographic and organizational factors on participation and detection rates. 
Some studies have shown that participation is higher in women than in men (Klabunde et al., 
2015; Portillo et al., 2013; Molina-Barceló et al., 2016, Clarke et al., 2015), especially in those 
aged 50-59 years (Salas et al., 2014).  
Participation has also been related to area of residence and socioeconomic status. A study 
performed in The Netherlands showed that high participation was related to living in a rural 
area and having high socioeconomic status (Hol et al., 2010), another study from United States 
concluded that the likelihood of adherence to CRCSP was lower in residents of rural areas 
















socioeconomic status with different results (Molina-Barceló et al., 2014; Hurtado et al., 2015; 
Burón et al., 2015). 
Various studies have shown that individual screening history is associated with participation in 
subsequent rounds, with persons attending previous rounds being more likely to attend 
subsequent screening (Lo et al., 2014). In addition, repeat invitations to persons not accepting 
previous invitations can increase uptake (Steele et al., 2010). 
Participation is also influenced by the organizational features of CRCSP. Thus, uptake increased 
by 10% when the screening invitation was accompanied by a general practitioner’s 
endorsement and a leaflet explaining in detail how to complete the FOBT (Hewitson et al., 
2011). Another strategy to enhance participation is sending an advance notification letter 
(Senore et al., 2015). 
An analysis of the information available on effective interventions to increase participation in 
CRCSP concluded that educational interventions and organizational measures are required to 
enhance the impact of CRCSP (Senore et al., 2015). Another European study compared distinct 
forms of FOBT delivery and found that participants receiving the FOBT kit with the invitation 
had a significantly higher likelihood of participating than persons who received a letter of 
invitation asking them to collect the FOBT kit in the health center (Van Roosbroeck et al.; 
2012). 
In Spain, the population eligible for CRCSP consists of asymptomatic men and women, with no 
prior history of CRC, aged between 50 to 69 years, the age group at highest risk. The target 
population is invited to complete an FOBT every 2 years and persons with a positive result are 
offered diagnostic confirmation through colonoscopy (Salas Trejo et al., 2016). There are 17 
Spanish regions with autonomy in the organization of certain health services. Each region has 
developed and implemented a CRCSP since 2000, which has been progressively expanded. In 
2012, coverage was 17%. Although the methodological foundations (ie, target population, 
screening intervals) are common to all programs, there are some organizational differences 
between regions, such as the type of invitation (affecting FOBT delivery) and the type of FOBT 
offered. 
The first autonomous communities implementing CRCSP in Spain participated in the CRIBEA 
research project, whose aim is to evaluate the impact of CRCSP in Spain.  
Given the scarcity of studies on this topic, the aim of this study was to estimate uptake of 
















sociodemographic factors, such as age, sex, municipality of residence, FOBT delivery type, type 
of FOBT and screening history on participation rates.  
 
Methods 
The CRIBEA Project 
The CRIBEA Project is a retrospective study of a cohort of men and women aged 50 to 69 years 
taking part in the 6 CRCSP in Spain that participate in the project: Catalonia, the Valencian 
Community, Murcia, Cantabria, the Canary Islands, and the Basque Country. The project aims 
to identify the factors that could influence the balance between predictors of benefits and 
harms in CRCSP. The study was approved by the Clinical Research Ethics Committee of the 
General Directorate of Public Health and the Public Health Research Center of the Valencian 
Community. 
Information was gathered on invitations sent since the start of each CRCSP until December 31, 
2012. All CRCSP are based on biennial FOBT (rounds), i.e., the target population are invited to 
undergo FOBT every 2 years and, in 2012, at least 2 rounds had been completed. All programs 
are population-based, ie, individual letters of invitation are sent to the entire target population 
a reminder is sent to non-participants. All the CRCSP use FOBT (Salas Trejo et al., 2017) and 
inform participants of negative and positive results and schedule a colonoscopy in persons 
with a positive result. The organizational features of the CRCSP included in the study are 
shown in Table 2. 
 
Population 
To conduct the CRIBEA project, a database common to the CRCSP was constructed (Table 3), 
linking all the information on each of the invitations issued during the study period. The 
database contained information on 1,995,719 invitations sent to 1,320,300 persons. Persons 
whose invitations were sent to the wrong address and those with a prior colonoscopy were 
excluded. The population is a dynamic cohort, with members leaving and being added over 
time, depending on their age.  
The participation study analyzed the invitations of the first 3 screening rounds. The sample 
















invitation were excluded. Among the data analyzed, each person is linked to one of the 6 
CRCSP. Because a single person can have 1 to 3 invitations, the data have a repeated measures 
structure.    
In this study, we analyzed the sample by stratifying it in four groups by type of screening 
(Segnan et al., 2010): (Table 1) 
Initial Screening-first invitation: persons receiving a first invitation to CRCSP, independently of 
the organizational round of the program.  
Subsequent invitation for previous never-responders: persons invited to previous rounds but 
who had not participated.  
Subsequent invitation-regular intervals (adherence): previously-invited persons who had 
participated in the previous round.  
Subsequent invitation-irregular intervals: invited persons who had not participated in the 
immediately previous round but who had participated in at least one prior round. 
 
Response variable: 
Participation: persons invited for screening who returned the FOBT, independently of the 
result (positive, negative, weak positive, technical error, and unknown).  
 
Explanatory variables: 
Age and sex groups:  women aged 50-59 years and 60-69 years, men aged 50-59 years and 60-
69 years. Age at the time of invitation was analyzed.  
Area of residence: municipalities with less than 5,000 inhabitants were defined as rural, those 
with between 5,000 and 10,999 inhabitants as semi-rural, and those with more than 10,000 
inhabitants as urban.  
FOBT delivery type: This variable concerned how each participant obtained the FOBT kit. There 
were three modalities. 
Active collection: a letter of invitation is sent and the FOBT is collected from a retail pharmacy 
















Minimal action: a letter of invitation is sent and the person confirms his or her wish to 
participate by postcard, telephone call, etc.; the person is then sent an FOBT kit.  
No action: the FOBT is sent directly with the letter of invitation. 
Type of FOBT: Guaiac (gFOBT), quantitative immunological (quantitative FIT), or qualitative 
immunological (qualitative FIT). 
 
Statistical analysis: 
To include the experience of each patient in the CRCSP, participation was analyzed by 
stratifying the sample by screening type. Initial participation was studied by analyzing 
participation in the first invitation and in Subsequent invitation for previous never-responders. 
Subsequent screening participation was analyzed through study of participation in Subsequent 
invitation-regular intervals and Subsequent invitation-irregular intervals. 
Because individuals could receive more than one invitation, each data group had a repeated 
measures structure, except the groups of Initial screening-first invitation and Subsequent 
invitation-irregular intervals (round 3 only), in which each individual had only one invitation.  
A descriptive analysis was conducted of the data collected in the CRIBEA study and the data 
from the three rounds analyzed in this study. For each round and each stratum, the number of 
invitations and the percentage of participation were analyzed.  
A descriptive analysis was performed of participation according to sociodemographic and 
organizational variables. The percentage of participation was calculated in each group, taking 
the number of participations as the numerator and the number of invitations sent as the 
denominator. The percentage of participation in Initial Screening was calculated globally, 
taking the number of invitations in Initial screening-first invitation as the denominator and the 
sum of participations, both in Initial screening-first invitation and in Subsequent invitation for 
previous responders, as the numerator. The chi-square test was used to study the relationship 
between explanatory variables and the response variable, with calculation of the 
corresponding p-value and 95% confidence intervals. Statistical significance was set at p < 0.05. 
To explain participation in terms of organizational and sociodemographic factors of the CRCSP, 
a mixed logistic regression model was adjusted in each stratum, considering random effects of 
















variable was participation and the explanatory variables were age and sex groups, area of 
residence, FOBT delivery type, and type of FOBT. The analysis was performed with the R 
statistical package, using the glmer function of the Ime4 library. 
 
Results 
A total of 1,748,753 invitations were analyzed. Among these, there were 852,497 FOBT, and 
17,506 persons were diagnosed with high- or intermediate-risk adenomas and 2,641 with CRC 
(Table 3).  
Participation was 52.9% in Initial screening overall, 48.8% in Initial screening-first invitation, 
17.7% in Subsequent invitation for previous never-responders, 85% in Subsequent invitation-
regular intervals and 37.8% in Subsequent invitation-irregular intervals (Table 4). 
Participation was higher in women aged 60-69 years in Initial screening-first invitation and in 
women aged 50-59 years in Subsequent invitation for previous never-responders. In 
Subsequent invitation-regular intervals, participation was higher in men and women aged 60-
69 years than in other age groups (Table 4).  
Uptake was higher when no action was required by the invited person to receive the FOBT. 
This association was maintained for all screening types, with participation being higher both in 
Initial Screening (no action 68.6%, minimal action 45.3%, active collection 47.4%) and in 
Subsequent invitation-regular intervals (no action 89.1%, active collection 77.4%) and most 
markedly in Subsequent invitation-irregular intervals (no action 57.9%, active collection 12.7%) 
(Table 4). 
Participation was higher when the FIT type was quantitative compared with qualitative and 
gFOBT in Initial Screening but not in successive screening-regular intervals, in which 
participation rates were similar between quantitative FIT and gFOBT.  
Uptake was higher with quantitative FIT than with qualitative FIT and gFOBT in Initial Screening 
but not in subsequent screening-regular intervals, in which participation rates were similar 
between quantitative FIT and gFOBT.  According to the chi-square test all explanatory variables 


















Initial participation  
In the Initial screening-first invitation model, participation was higher in women aged 50-59 
years (OR 1.05; 95% CI 1.05 to 1.06) and in those aged 60-69 years (OR 1.12; 95% CI 1.11 to 
1.14) than in men aged 60-69 years. Uptake was higher in rural and semi-rural populations 
than in urban populations and was higher when no action was required to receive the FOBT 
(OR 2.24; 95% CI 2.21 to 2.26) and lower when minimal action was required (OR 0.74 95% CI 
0.73 to 0.75) than when active collection was required. Participation was also statistically 
significantly higher with the quantitative FIT (Table 5). 
In the model for Subsequent invitation for previous never-responders, participation was higher 
in women aged 50-59 years (OR 1.09; 95% CI 1.06 to 1.16) and 60-69 years (OR 1.08; 95% CI 
1.05 to 1.11) than in men aged 60-69 years. Participation was also higher in rural populations, 
and when minimal action (OR 1.57; 95% CI 1.53 to 1.62) or no action (OR 2.14; 95% CI 2.08 to 
2.21) was required than when active collection was required to receive the FOBT. Participation 
was statistically significantly higher when the quantitative FIT was used (Table 5). 
 
Subsequent participation  
Participation in Subsequent invitation-regular intervals or adherence to screening was 
statistically significantly higher in men and women aged 60-69 years than in younger men and 
women and in rural and semi-rural areas, participation was higher when no action was 
required to receive the FOBT kit (OR 2.03; 95% CI 1.96 to 2.11) than when active collection was 
required. Adherence was statistically significantly greater when the quantitative FIT was used 
(Table 6). 
In the Subsequent invitation-irregular intervals model, participation did not statistically 
significantly by age and sex but was statistically significantly higher in rural areas. Uptake was 






















Together with other indicators, participation is an indicator that measures the impact of 
CRCSP. Consequently, guidelines establish acceptable standards that guarantee the quality of 
these programs (Segnan et al., 2010). In Spain, the CRCSP have shown that indicators of the 
detection rate are within the ranges recommended by guidelines (Portillo et al., 2017). If these 
indicators are adequate, improving participation will enhance the impact of the programs. Our 
study shows the influence on participation of organizational factors such as the type of FOBT 
delivery and the type of FOBT (guaiac and qualitative or quantitative immunological) offered 
by CRCSP. 
This study demonstrates that initial and successive participation in screening was increased by 
the inclusion of the FOBT kit in the letter of invitation. This factor was especially important in 
persons with the greatest difficulty in participating, such as those in the groups of Subsequent 
invitation for previous never-responders and Subsequent invitation-irregular intervals, with 
participation being up to 9.4 times higher in this latter group if the FOBT kit was mailed with 
the invitation. These results are in line with a study conducted in Belgium reporting that the 
probability of participation was twice as high in persons who received the FOBT kit together 
with a letter of invitation than in those receiving a letter of invitation with an indication to 
collect the kit from the general practitioner (Van Roosbroeck et al.; 2012). 
The disadvantage of including the FOBT kit with the letter of invitation is that unused tests are 
wasted. Consequently, cost-effectiveness studies are needed that analyze participation rates in 
each program.  
Uptake seems to be strongly influenced by the type of test employed, and rates are highest 
when the FIT is used, as shown by Chambers et al. (2016), although no differences have 
previously been demonstrated between quantitative and qualitative FIT. The results of the 
present study show higher participation rates with the quantitative FIT. The FIT is the easiest 
to use by the population and, in the context of the organization of screening programs, is also 
preferred because of its homogenous and automatic classification of the population.  
For programs to be effective, the European guideline for CRC screening recommends target 
participation rates higher than 65% and considers an acceptable rate to be 45% (Segnan N et 
al., 2010). In our study, the participation rate in Initial Screening was 53%, which, according to 
the guideline, is acceptable but is lower than recommended rates (Segnan N et al., 2010). 
















irregular intervals group, which had below the recommended percentage of participation, are 
direct delivery of the FOBT kit and the use of quantitative FIT. A study comparing CRCSP 
internationally concluded that comparisons between CRCSP should take into account 
organizational differences, target populations, and the interpretation of indicators (Klabunde 
et al., 2015). 
Our study found higher initial participation and adherence to screening in rural or semi-rural 
areas. This finding concurs with a study conducted in The Netherlands (Hol et al., 2010), but 
there is no consensus in the literature on the influence of geographical region on participation 
in CRCSP in the United States, where one study demonstrated lower participation rates in rural 
areas, due to reduced access to health service coverage in these locations (Wools et al., 2016). 
In Spain, as in most European programs but unlike those in the US, FOBT is only offered in 
population-based screening programs. Moreover, in Spain, where health service coverage is 
similar in all geographical areas, this factor seems to be positive due to the possible closeness 
of health services. A Spanish study analyzed the influence of being informed of CRCSP and 
participation, as well as the role of primary care physicians on being informed (Molina-Barceló 
et al., 2016). The present study could not examine the influence of primary care physician 
recommendation on participation as this information was not available, but rural populations 
seem to have a more direct physician-patient relationship.   
As observed in other studies, participation in CRCSP is influenced by age and sex, with 
participation in Initial screening-first invitation being higher in women (Portillo et al., 2013; 
Clarke et al., 2015; Molina-Barceló et al., 2014) and in persons aged 60-69 years than in 
persons aged 50-59 years (Salas et al., 2014). In contrast, adherence to screening among 
persons with previous participation showed differences by age but not by sex, with lower 
participation among young men and women, as reported in other studies (Ricardo-Rodrigues 
et al., 2015; Steele et al., 2010). The disappearance of differences by sex could be due to a 
selection effect, since participation in successive screening depends on previous participation. 
Efforts to increase participation in men should therefore focus on initial invitations.  
This study has some limitations. First, the qualitative FIT was used in only one regional CRCSP, 
which also requires active collection of the FOBT kit, which could have influenced the results 
regarding this test. Second, the programs were implanted over a long period and, during the 
study period, not all programs had completed the first 3 rounds.  
Among the strengths of this study are that it analyzes population-based data, drawn from 
















screening rounds (the first 3 rounds). A further strength is that this study analyzed the effects 
of distinct organizational types in a population that was similar in terms of age and sex.  
The results of our study indicate that organizational strategies that enhance participation are 
the use of FIT rather than gFOBT and reducing the effort required to receive the FOBT. These 
results have important implications for CRCSP using the FOBT and could be applicable to other 
CRCSP. Moreover, our results identify certain factors such as age, sex, and geographical area of 
residence, for which specific invitation strategies could be designed to boost participation or 
increase levels to those found for other groups. Obviously, these strategies should be carried 
out within the framework of participation based on an informed decision on the benefits and 
harms of screening.   
It is important to know each individual´s screening history when sending an invitation as well 
as to monitor and analyze participation in CRCSP and search for strategies that could improve 
results to allow long-term evaluation of reductions in CRC-related mortality and the incidence 
of this tumor.  
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Table 1. Number of invitations analyzed by round and screening type  
  








N (% participation) N (% participation) N (% participation) N (% participation) 
1st round  1 044 847 (50.3%)       
          
2nd round  126 350 (42.1%) 182 834 (20.6%) 186 987 (85.2%)   
          
3rd round  44 618 (33.7%) 101908 (12.53%) 56 093 (84.55%) 5 116 (37.8%) 
          
Total 1 215 815 (48.8%) 284 742 (17.7%) 243 080 (85.0%) 5 116 (37.8%) 
aCRCSP from Catalonia, Valencian Community, Murcia, Cantabria, the Canary Islands, and the Basque Country 


































Catalonia 2000 50-69 gFOBT (until 2009) 
FIT QT (since 2009) 






Valencian Community 2005 50-69a gFOBT (until 2010) 
FIT QT (since 2010) 
2 1 Minimal action Minimal action 
No action 
4 















Basque Country 2009 50-69 FIT QT 2 1 No action No action 2 
FOBT, Fecal Occult Blood Test; FIT, Fecal Immunochemical Test; QT, Quantitative; QL, Qualitative 


















Table 3. Sample size of the main indicators of the CRIBEA project and the present study. 
 
CRIBEA Project population Study population  
 Number of invitations 1,995,719 1,748,753 
Number of participations 931,919 852,497 
Number of FOBT analyzed  54,918 51,687 
Number of colonoscopies 48,730 45,786 
People with low-risk adenomas 9,219 8,721 
People with intermediate- or high-
risk adenomas 18,415 17,506 
People with colorectal cancer. 2,813 2,641 
FOBT, Fecal Occult Blood Test;  
Number of people with low-risk adenomas were defined as those with one or two adenomas and both less than 
10mm containing neoplasia in low-grade mucosa and tubular component  
Number of people with high or intermediate risk adenomas: Number of people with an adenoma at least equal to 
or greater than 10 mm  or when there were 3 or more adenomas of any size or growth on the high-grade mucosa 
villous component (Carcinoma "in situ" was included in this category) 



















Table 4. Percentages of participation by invited/screened individuals and sociodemographic 
and organizational variables of the PPCCR, percentage of participation (%) and denominator 
(N)  



















 % % (N) % (N) % (N) % (N) 
Total participation 52.9 48.8 (1215815) 17.7 (284742) 85.0 (243080) 37.8 (5116) 
Age and sex groups 
   Men 60-69 years 54.2 49.1 (242572) 17.2 (71540) 86.1 (59770) 42.9 (1507) 
   Men 50-59 years 48.0 44.6 (345730) 16.8 (70352) 83.1 (48773) 28.7 (942) 
   Women 60-69 years 56.8 51.7 (266999) 18.2 (74517) 85.9 (74268) 43.1 (1732) 
   Women 50-59 years 54.1 50.5 (360514)d  18.8 (68333)d  84.4 (60269)d  28.8 (935)d  
Area of residence  
   Rural 54.0 50.4 (105482) 17.0 (22482) 84.8 (20103) 47.2 (638) 
   Semi-rural 59.1 56.3 (90150) 16.0 (15870) 86.0 (19540) 30.0 (646) 
   Urban 52.3 48.0 (1019984)d  17.9 (246358)d  85.0 (203435)d  37.5 (3832)d  
FOBT delivery type 
   Active collection 47.4 44.7 (480372) 13.3 (98188) 77.4 (84311) 12.7 (2276) 
   Minimal actionb 45.3 38.1 (378815) 17.8 (153432)   
   No action  68.6 65.8 (356377)d 30.0 (32989)d  89.1 (158769)d  57.9 (2840)d  
FOBT type 
   quantitative FIT c 56.1 52.3 (908572) 18.9 (184357) 86.4 (198903) 37.8 (5116) 
   gFOBT 46.9 39.1 (197366) 17.6 (86993) 87.4 (34418)  
   qualitative FIT  38.9 38.6 (105992)d  2.3 (13265)d 48.8 (9759)d    
FOBT, fecal occult blood test; FIT immunological FOBT; gFOBT guaiac FOBT. 
a Denominator=initial screening-first invitation, numerator = initial participation-first invitation + subsequent 
participations in never-responders.  
b The invitation type of minimal action was not used in subsequent invitation-regular intervals and subsequent 
invitation-irregular intervals. 



















Table 5. Multivariate models for initial participation by sociodemographic and organizational 
factors of the CRCSP.  
 Initial screening-first 
invitationa 
Subsequent invitation for 
previous never 
respondersa 
 OR 95% CI OR 95% CI 
Age and sex groups     
   Men 60-69 years 1  1  
   Men 50-59 years 0.82 0.81 to 0.82 0.93 0.91 to 0.96 
   Women 60-69 years 1.12 1.11 to 1.14 1.08 1.05 to 1.11 
   Women 50-59 years 1.05 1.04 to 1.06 1.09 1.06 to 1.16 
Area of residence      
   Rural 1  1  
   Semi-rural 1.09 1.07 to 1.11 0.86 0.82 to 0.91 
   Urban 0.82 0.81 to 0.83 0.95 0.92 to 0.99 
FOBT delivery type     
   Active collection 1  1  
   Minimal action  0.74 0.73 to 0.75 1.57 1.53 to 1.62 
   No action 2.24 2.21 to 2.26 2.14 2.08 to 2.21 
FOBT type      
   quantitative FIT 1  1  
   gFOBT 0.81 0.80 to 0.82 0.88 0.86 to 0.90 
   qualitative FIT 0.70 0.69 to 0.71 0.12 0.11 to 0.14 
Random effects     
   Variation (standard error)   
  
individual  0.026 (0.162) 
OR, odds ratio; CI, confidence interval; FOBT, fecal occult blood test; FIT immunological FOBT; gFOBT guaiac FOBT. 


















Table 6. Multivariate models for successive participation by sociodemographic and 







OR 95% CI OR 95% CI 
Age and sex groups     
   Men 60-69 years 1  1  
   Men 50-59 years 0.75 0.72 to 0.77 1.04 0.85 to 1.27 
   Women 60-69 years 0.99 0.96 to 1.02 1.01 0.87 to 1.18 
   Women 50-59 years 0.84 0.82 to 0.87 1.11 0.91 to 1.36 
Area of residence     
   Rural 1  1  
   Semi-rural 1.12 1.06 to 1.19 0.74 0.57 to 0.96 
   Urban 0.93 0.89 to 0.98 0.77 0.964 to 0.93 
FOBT delivery type     
   Active collection 1  1  
   No action  2.03 1.96 to 2.11 9.38 8.06 to 10.91 
FOBT type     
   quantitative FIT 1    
   gFOBT 0.73 0.70 to 0.76   
   qualitative FIT 0.20 0.19 to 0.21   
Random effects     
   Variation (standard error) individual  0.108(0.328)     
OR, odds ratio; CI, confidence interval; FOBT, fecal occult blood test; FIT immunological FOBT; gFOBT guaiac FOBT. 






















 Organizational features of CRCSP can enhance participation rates. 
 Participation was analyzed by FOBT delivery type and the type of FOBT offered. 
 Sociodemographic factors were included in the study of CRCSP participation. 
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